A Randomized, Double-Masked, Placebo-Controlled Clinical Trial of Two Forms of Omega-3 Supplements for Treating Dry Eye Disease
Deinema LA, Vingrys AJ, Wong CY, Jackson DC, Chinnery HR, Downie LE
Ophthalmology · 112 citas
Etiquetas de revisión
Financiación no declaradaDatos neutrales que nuestra revisión registró sobre cómo se hizo este estudio. Describen el método, nunca si nos gusta el resultado.
Cómo se estudió
- Diseño
- Ensayo controlado aleatorizado (indexado por PubMed)
- Estudiado en
- Personas
- Resultado principal
- Marcadores de salud y funcionamiento
Quién lo pagó
- Financiación
- Financiación no declarada
Publicación
- Publicado
- 2016-11-03 · Ophthalmology · vol. 124 · número 1 · págs. 43–52
- Editorial
- Elsevier BV
- Citado
- 159 citas · más que el 99% de estudios similares · 16.9× el promedio de su campo
- Impacto
- Entre el 10 % más citado de su campo
- Referencias
- 66 trabajos
- Acceso
- Lectura gratuita
- Áreas de investigación
- Ocular Surface and Contact Lens · Fatty Acid Research and Health · Retinal Diseases and Treatments
- Palabras clave
- dry eye, omega-3 supplementation, krill oil, fish oil, eicosapentaenoic acid, docosahexaenoic acid, tear osmolarity, tear film break-up time, meibomian gland dysfunction, meibography
- MeSH
- tears, animals, humans, euphausiacea, dry eye syndromes, fatty acids, omega-3, phospholipids, fish oils, cytokines, double-blind method, visual acuity, osmolar concentration, dietary supplements, adult, middle aged, female, male
6 autores
- Laura A. Deinema🇦🇺The University of Melbourne
- Algis Jonas Vingrys🇦🇺The University of Melbourne
- Chinn Yi Wong🇦🇺The University of Melbourne; Peter Doherty Institute
- David Charles Jackson🇦🇺The University of Melbourne; Peter Doherty Institute
- Holly Rose Chinnery🇦🇺The University of Melbourne
- Laura Elizabeth Downie🇦🇺 · autor de correspondenciaThe University of Melbourne
Resumen
El texto original del estudio, en el idioma en que se publicó.
Purpose
To assess the efficacy of 2 forms of oral long-chain omega-3 (ω-3) essential fatty acid (EFA) supplements, phospholipid (krill oil) and triacylglyceride (fish oil), for treating dry eye disease (DED).
Design
Randomized, double-masked, placebo-controlled clinical trial.
Participants
This study was conducted at a single site and involved 60 participants with mild to moderate DED who were randomized (1:1:1) to 1 of 3 groups: placebo (olive oil), krill oil, or fish oil supplements.
Methods
Participants received 1 of the 3 interventions: placebo (olive oil 1500 mg/day), krill oil (945 mg/day eicosapentaenoic acid [EPA], + 510 mg/day docosahexaenoic acid [DHA]), or fish oil (1000 mg/day EPA + 500 mg/day DHA) for 90 days, with monthly study visits.
Main outcome measures
Primary outcome measures were mean change in (1) tear osmolarity and (2) DED symptoms (Ocular Surface Disease Index [OSDI] score) between days 1 and 90. Secondary outcomes included mean change in key clinical signs (tear stability, tear production, ocular surface staining, bulbar and limbal redness, tear volume, anterior blepharitis, meibomian gland capping) and tear inflammatory cytokine levels.
Results
In total, 54 participants completed the study. At day 90, tear osmolarity was reduced from baseline with both krill oil (mean ± standard error of the mean: -18.6±4.5 mOsmol/l; n = 18; P < 0.001) and fish oil (-19.8±3.9 mOsmol/l; n = 19; P < 0.001) supplements, compared with placebo (-1.5±4.4 mOsmol/l; n = 17). OSDI score was significantly reduced at day 90 relative to baseline in the krill oil group only, compared with placebo (-18.6±2.4 vs. -10.5±3.3; P = 0.02). At day 90, there were also relative improvements in tear breakup time and ocular bulbar redness, compared with placebo, for both forms of ω-3 EFAs. Basal tear levels of the proinflammatory cytokine interleukin 17A were significantly reduced in the krill oil group, compared with placebo, at day 90 (-27.1±10.9 vs. 46.5±30.4 pg/ml; P = 0.02).
Conclusions
A moderate daily dose of both forms of long-chain ω-3 EFAs, for 3 months, resulted in reduced tear osmolarity and increased tear stability in people with DED. Omega-3 EFAs in a predominantly phospholipid form (krill oil) may confer additional therapeutic benefit, with improvements in DED symptoms and lower basal tear levels of interleukin 17A, relative to placebo.
Resumen vía Europe PMC. Los derechos de autor siguen siendo de los autores o la editorial.
Confianza de la comunidad
Cargando…
¿Cuánto confías en los hallazgos de este estudio?
Comentarios
¿Algo está mal aquí?
Señala este estudio si su información, etiquetas o financiación parecen incorrectas. Un editor revisa cada señalamiento.
Información educativa sobre investigación publicada. No es consejo médico ni una recomendación para empezar o dejar nada.